Retrospective Cohort Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jul 27, 2024; 16(7): 2023-2030
Published online Jul 27, 2024. doi: 10.4240/wjgs.v16.i7.2023
Application of radioactive iodine-125 microparticles in hepatocellular carcinoma with portal vein embolus
Peng Meng, Ji-Peng Ma, Xiao-Fei Huang, Kang-Le Zhang
Peng Meng, The Fourth Department of Oncology, Yantai Hospital of Traditional Chinese Medicine, Yantai 264001, Shandong Province, China
Ji-Peng Ma, Department of Medical Services, Yantai Hospital of Traditional Chinese Medicine, Yantai 264001, Shandong Province, China
Xiao-Fei Huang, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510062, Guangdong Province, China
Kang-Le Zhang, The Third Department of Oncology, Yantai Hospital of Traditional Chinese Medicine, Yantai 264001, Shandong Province, China
Co-first authors: Peng Meng and Ji-Peng Ma.
Author contributions: Meng P and Ma JP wrote the manuscript and contributed equally to this work; Huang XF collected the data; Zhang KL guided the study; All authors reviewed, edited, and approved the final manuscript and revised it critically for important intellectual content, gave final approval of the version to be published, and agreed to be accountable for all aspects of the work.
Institutional review board statement: This study was approved by the Medical Research Ethics Committee of The First Affiliated Hospital of Sun Yat-sen University.
Informed consent statement: This study has obtained the informed consent of the patients and their families who signed the informed consent for treatment.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Data sharing statement: Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested. E-mail: zhangkangle1987@163.com.
STROBE statement: This study complied with STROBE statement, ensuring transparency and accuracy in study design, data analysis and reporting of results.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kang-Le Zhang, Doctor, The Third Department of Oncology, Yantai Hospital of Traditional Chinese Medicine, No. 39 Xingfu Road, Zhifu District, Yantai 264001, Shandong Province, China. zhangkangle1987@163.com
Received: May 2, 2024
Revised: May 22, 2024
Accepted: June 13, 2024
Published online: July 27, 2024
Processing time: 80 Days and 21.5 Hours
Core Tip

Core Tip: This study investigated the clinical value of radioactive iodine-125 (125I) particles in the treatment of hepatocellular carcinoma with portal vein embolism. The study reviewed data from patients who received 125I microparticle implantation to evaluate its effect on tumor control and survival. At the same time, monitoring treatment-related safety and complications provided a basis for evaluating the efficacy and risk of 125I particles in this pathological scenario.